Condition
Metastatic Cutaneous Squamous Cell Carcinoma
Total Trials
3
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07288073Phase 2Recruiting
TIL Therapy in cSCC and MCC
NCT04305795Phase 1Active Not Recruiting
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
NCT04050436Phase 2Active Not Recruiting
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Showing all 3 trials